drugset / Trial / NCT01634503
Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to determine maximum tolerable dose (MTD) of GX 188E by defining the safety profile the safety and maximum tolerated dose of GX-188E administered by electroporation in Cervical Intraepithelial Neoplasia grade 3 (CIN 3) patients.
Timeline
- Start
- 2012-11
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GX-188E | Vaccine | 1 mg | Intramuscular |
| Subject | GX-188E | Vaccine | 2 mg | Intramuscular |
| Subject | GX-188E | Vaccine | 4 mg | Intramuscular |